Versantis
A Swiss pharmaceutical company developing new generations of liver disease medicines and diagnostics.
Launch date
Employees
Market cap
-
Enterprise valuation
$72—108m (Dealroom.co estimates Sep 2019.)
Company register number CH-020.3.041.748-6
Zurich Canton of Zürich (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
CHF1.0m | Seed | ||
N/A | Spinout | ||
CHF100k | Early VC | ||
$4.5m | Series A | ||
$18.0m | Series B | ||
* | N/A | $16.0m | Series B |
* | CHF480k | Grant | |
* | CHF40.0m | Acquisition | |
| Total Funding | $39.9m | ||
Related Content
Recent News about Versantis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.